Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma. by Jayachandran, A, Anaka, M, Prithviraj, P, Hudson, C, McKeown, S, Lo, P, Vella, L, Goding, C, Cebon, J, Behren, A

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. by Petrella, T, Robert, C, Richtig, E, Miller, W, Masucci, G, Walpole, E, Lebbe, C, Steven, N, Middleton, M, Hille, D, Zhou, W, Ibrahim, N, Cebon, J

NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus. by Chen, J, Dawoodji, A, Tarlton, A, Gnjatic, S, Tajar, A, Karydis, I, Browning, J, Pratap, S, Verfaille, C, Venhaus, R, Pan, L, Altman, D, Cebon, J, Old, L, Nathan, P, Ottensmeier, C, Middleton, M, Cerundolo, V

Correction: restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP by Lu, M, Breyssens, H, Salter, V, Zhong, S, Hu, Y, Baer, C, Ratnayaka, I, Sullivan, A, Brown, N, Endicott, J, Knapp, S, Kessler, B, Middleton, M, Siebold, C, Jones, E, Sviderskaya, E, Cebon, J, John, T, Caballero, O, Goding, C, Lu, X

Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. by Lu, M, Breyssens, H, Salter, V, Zhong, S, Hu, Y, Baer, C, Ratnayaka, I, Sullivan, A, Brown, N, Endicott, J, Knapp, S, Kessler, B, Middleton, MR, Siebold, C, Jones, E, Sviderskaya, E, Cebon, J, John, T, Caballero, O, Goding, C, Lu, X

Frequent MAGE mutations in human melanoma. by Caballero, O, Zhao, Q, Rimoldi, D, Stevenson, B, Svobodová, S, Devalle, S, Röhrig, U, Pagotto, A, Michielin, O, Speiser, D, Wolchok, J, Liu, C, Pejovic, T, Odunsi, K, Brasseur, F, Van den Eynde, B, Old, L, Lu, X, Cebon, J, Strausberg, R, Simpson, A